In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Trial of Intensified (BNP-guided) versus standard (symptom-guided) Medical therapy in Elderly patients with Congestive Heart Failure TIME-CHF.

Hot Line I

Heart Failure (HF)

Presenter report:
Brunner-La Rocca, Hans Peter (Switzerland)

Background: It is uncertain whether intensified, NT-BNP-guided therapy of heart failure (HF) improves outcome compared to standard, symptom-guided therapy, and whether there is a difference in the response in patients ≥ versus <75 years of age.

Methods: Therefore, 499 patients with systolic HF (ejection fraction 45%) were randomised to an NT-BNP-guided or a symptom-guided strategy and stratified into patients aged ≥75 versus 60-74years. Included were patients with dyspnea NYHA≥II, HF hospitalizations within one year and NT-BNP levels >400pg/ml (60-74years) or 800pg/ml (≥75years). Therapy was uptitrated according to guidelines aiming to reduce symptoms to NYHA£II or additionally NT-BNP-levels below levels mentioned above. The primary endpoint was survival free of all-cause hospitalisations up to 18 months and quality of life. Secondary endpoints were survival and HF hospitalization-free survival.

Results: Compared to standard therapy, intensified treatment did not improve primary endpoint (hazard ratio (HR)=0.92, p=0.46), but did improve the more disease-specific endpoint of survival free of HF hospitalisations (HR=0.66, p=0.008). Intensified therapy reduced total mortality (HR=0.38, p=0.01) and improved survival free of HF hospitalisations (HR=0.41, p=0.002) in younger patients, but not in those 75years. In addition, quality of life improved less by intensified versus standard therapy in older patients despite similar reductions in symptoms and BNP-levels.

Conclusions: Intensified HF therapy did not improve overall outcome compared to standard treatment. However, it improved survival free of HF hospitalizations overall and it reduced mortality in patients <75 years of age, without similar benefits in older patients. Specific HF trials in very elderly patients are warranted.

Discussant: Dickstein, Kenneth (Norway)





Hot Line Update I

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.